Dianthus Therapeutics (DNTH) Gets a Buy From Wedbush

TipRanksMay 10 20:46

Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating

Dianthus Therapeutics (DNTH) has an average rating of buy and price targets ranging from $33 to $84, according to analysts polled by Capital IQ.

MT NewswiresMay 10 20:19

Dianthus Therapeutics | 10-Q: Quarterly report

Futu NewsMay 10 04:53 · Announcements

Dianthus Therapeutics Q1 EPS $(0.54) Misses $(0.44) Estimate, Sales $874.00K Beat $460.00K Estimate

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.44) by 22.73 percent. The company reported quarterly sales of $87

BenzingaMay 10 04:46

Dianthus Therapeutics 1Q Loss/Shr 54c >DNTH

Dianthus Therapeutics 1Q Loss/Shr 54c >DNTH

Dow JonesMay 10 04:06

Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing, with top-line results anticipated in

Dow JonesMay 10 04:01